LuTectomy enrolled 20 men with high PSMA-expressing, high-risk localized or locoregional advanced prostate cancer and evaluated the dosimetry, safety, and efficacy of upfront 177Lu-PSMA-617 prior to radical prostatectomy with pelvic node lymph node dissection. The gene discussed is FOLH1; the disease is prostate cancer.